CorMedix Gives Update on Phase 3 Clinical Program for Neutrolin

CorMedix (NYSE:CRMD) shared an update to shareholders on their phase 3 clinical program for Neutrolin regarding a favorable correspondence with the FDA.
As quoted in the press release:

Based on a review of the status of the ongoing LOCK-IT-100 clinical study and a revised plan put forth by CorMedix, the FDA agreed to key changes to the study. The Company believes that the changes endorsed by the FDA will facilitate the company’s ability to complete the ongoing Phase 3 study as previously announced by year end 2018.
The Company sought guidance from the FDA to address, in part, the apparent overall lower rate of catheter-related blood stream infection (CRBSI) events as announced in April 2017.

Click here to read the full press release.

Source: www.accesswire.com